

# Brisbane Cancer Conference

25–26 November 2021

Brisbane Convention and Exhibition Centre

2021



## Conference Handbook



# Conference Sponsors

## Platinum Sponsors



## Gold Sponsor



## Silver Sponsors



## Bronze Sponsors



## Other Sponsors



## Institution Donations



# Welcome

Dear Colleagues,

Welcome to the 8th Annual Brisbane Cancer Conference. With the establishment of the Brisbane Diamantina Health Partners as an NHMRC Advanced Health Research and Translation Centre, this meeting is an opportunity to draw together cancer researchers in Brisbane and Queensland to advance collaborative efforts in cancer research. The meeting comprises plenary lectures and workshops on recent scientific, technological, nursing and medical advances in the diagnosis and treatment of malignant disease.

On Thursday 25th November the meeting will start with Breast Cancer, Prostate Cancer, Survivorship and Immunotherapy symposia running from 8am – 12pm in the morning. There will be satellite symposia at lunch-time followed by plenary lectures from 2 – 4pm and subsequently workshops in these areas running from 4.30 – 6.00pm.

**The Gala dinner will be held on Thursday evening offering the opportunity to socialise with colleagues particularly from other institutions in the city and from Queensland.**

The all-day session on Friday 26th November will include plenary lectures followed by tumour-site specific workshops in the morning and afternoon.

Throughout the meeting lectures will be given by Queensland oncology researchers that have contributed to global advances in our understanding of the epidemiology, molecular biology and treatment of malignant disease.

The final session will focus on a number of successful grant applications made by Queensland researchers and how we might improve on research funding for oncology in the future.

In the region of 1,000 delegates attended the event last year demonstrating the value of a truly multi-disciplinary annual Queensland Translational Cancer Conference in Brisbane.

This conference is made possible through the support of the PA Research Foundation and Brisbane Diamantina Health Partners, our many sponsors, the time and effort of the chairs who put the symposia and workshops together as well as Therese and the QUT Cancer and Ageing Research Program (CARP) team.

Best wishes for what should be an enjoyable and fulfilling two days.

Yours sincerely,



**Professor Ken O'Byrne**  
**Consultant Medical Oncologist**

Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology

Opens 7.00am	Registration
Coffee cart	Illumina
<b>Symposia (8.00–12.00)</b>	
<b>Survivorship (supported by MSD)</b>	
Arbour Level A2	
Chairs: Natalie Bradford, David Wyld	
<b>Session 1: The Evidence for practice implementation</b>	
8.00	Overview of program of work in models of cancer survivorship care – Patsy Yates
8.20	PROMS / PROMISE Trial – Penny Webb
8.35	PROCESS Trial – Vanessa Beesley
8.50	When children grow up: care for adult survivors of childhood cancer – Liane Lockwood
9.05	Questions and wrap up
<b>Session 2: Clinician and Consumer Experiences of Providing and Receiving Survivorship Care</b>	
Panel: Belinda Matigan, Zarnie Lwin, Victoria Donohue, Gary Power	
9.20	YA clinical perspective – Belinda Matigan
9.30	CALD clinician perspective – Zarnie Lwin
9.40	Navigating survivorship across different countries: consumer perspective – Victoria Donohue
9.50	Receiving services in QLD – Gary Power
10.00	Morning tea
<b>Session 3: Re-imagining survivorship care in Queensland</b>	
10.30	Workshop – All attendees
<b>Prostate Cancer (supported by Janssen)</b>	
Boulevard Level B1	
Chairs: Matt Roberts, Colleen Nelson	
<b>Multidisciplinary approach to prostate cancer care</b>	
8.00	Introduction – Chairs
8.05	Prostate cancer care on the front line – Natasha Roberts
8.20	Recent advances and controversies in PSA screening – Peter Swindle
8.45	NAVIGATE trial – Natalie Richards (Zoom)
9.10	Pelvic floor physio and MaTchUP trial – Paul Hodges
9.35	Overview of advances in systemic therapy in prostate cancer – Arun Azad (Zoom)
10.00	Morning tea
<b>The future for prostate cancer</b>	
10.30	Imaging and theranostics – Louise Emmett (Zoom)
11.00	Investigating the role of novel transcripts in the MYCN locus driving neuroendocrine prostate cancer – Rae Browne
11.20	Establishment of ductal adenocarcinoma xenograft – Mahasha Perera
11.40	Clinical trials overview in Australia – Ian Vela
<b>Immuno-oncology (supported by AstraZeneca)</b>	
Boulevard Level B2&3	
Chairs: Robert Mason, Bryan Chan	
8.00	The microbiome and immunotherapy in oncology – Antiopi Varelias
8.20	Advances in I-O therapy – Melanoma and Merkel cell tumours – Wen Xu – Lung cancer: focus on early disease – Bryan Chan – Breast cancer – Catherine Shannon – Gastro-intestinal malignancy – Vladimir Andelkovic
9.30	Establishment on a rapid access I-O toxicity clinic – Robert Mason & Haakan Jakobsson
10.00	Morning tea
10.30	Prognostic and predictive biomarkers for I-O therapies – Ken O'Byrne
11.00	Overcoming resistance to I-O therapy – Rahul Ladwa
11.30	Cell based therapies in solid tumours – Ben Solomon (Zoom)

Breast Cancer (Supported by Novartis)		Boulevard Room
Chairs: Kate Cuff, Jasotha Sanmugarajah		
<b>Clinical and Translational Breast Cancer Research</b>		
8.00	Transforming breast cancer screening with Artificial Intelligence – Helen Fraser ((ZOOM)	
8.25	Optimal Breast Cancer Management: Striving for System Connectedness – Owen Ung	
8.50	Building the evidence for survivorship care models in breast cancer – Patsy Yates	
9.15	The effect of exercise on the prevention and treatment of cancer-related lymphoedema: results of a systematic review and meta-analysis – Sandi Hayes	
9.40	Targeting breast cancer therapy from a unique perspective: Novel agents that up-regulate the potent metastasis suppressor, NDRG1 – Des Richardson	
10.00	Morning tea	
Chairs: Margot Lehman, Peter Simpson		
10.30	CDK4/6 inhibition in cancer: beyond cell cycle arrest – Shom Goal (Zoom)	
11.00	Update on recruiting breast cancer trials in SEQ – Kate Roberts	
11.20	A spatially resolved single-cell atlas of localised breast cancer – Dan Roden (Zoom)	
11.40	Overcoming therapy resistance by targeting histone modifying enzymes in breast cancer – Jason Lee	
12.00	Refreshments	
Lunchtime sponsored symposia (12.15–13.45)		Boulevard Room
MSD: Optimal Oncology Clinics in 2022 and beyond – perspectives on the current lay of the land across both metro and regional treatment centres in Queensland (12.15–13.00)		
Chair: Melissa Eastgate		
12.15	Welcome and Introduction	
12.20	What are the current challenges? Panel Discussion: Melissa Eastgate, Kelli Brittain, Jasotha Sanmugarajah	
12.35	Solutions: What optimal looks like? Panel Discussion: Melissa Eastgate, Kelli Brittain, Jasotha Sanmugarajah	
12.50	Wrap Up and Close	
Astrazeneca: Fighting frailty in lung cancer (13.00–13.45)		
Chairs: Heather Lane, Rahul Ladwa		
13.00	Challenges of Frailty in Cancer Management – Darshit Thaker	
13.15	The Future of Managing Frailty in Cancer – James Fletcher	
13.30	Integration of Geriatric Health Care for Older Adults with Cancer – Heather Lane & Robyn Berry	
13.45	Lunch	
Plenary Lectures (14.00–16.00)		Boulevard Auditorium
Chairs: Damian Topp, Miriam Dwyer		
14.00	Is 'Big Data' enough? – Shoni Philpot	
14.19	Adolescent and young adult cancer outcomes in Queensland – Rick Walker	
14.38	Breast cancer risk and germline genomics – Jonathan Beasley	
14.57	Targeting DNA repair – Derek Richard	
15.15	Queensland Bladder Cancer Initiative – Elizabeth Williams (Zoom)	
15.30	Marijuana: the clinic – Padmini Menon	
15.45	Medicinal cannabis: weeding out the truth from fiction – Janet Hardy	
16.00	Refreshments	

#### Parallel Workshops (16.30–18.00)

##### Clinical trials

Arbour level A2

**Chairs: Adam Stoneley, Suzanne Elliott**

**Title: Innovations and applications supporting Oncology Clinical Trials in the era of COVID-19**

16.30	Session Introduction
16.35	SiteDocs Portal – Allan Bukuya
16.45	Gallipoli Medical Research Foundation – Vanessa Irvine
16.55	Sunshine Coast University Clinical Trials – Georgina Street
17.05	Princess Alexandra Hospital – Annabel Webber
17.15	IQVIA – Elizabeth Wilson
17.25	Mater Research – Amit Hayer
17.35	Royal Brisbane and Women's Hospital – Annette Cubitt & Amy Ives
17.45	Icon Cancer Centre – Jenny Pavlides
17.55	Discussion/Q&A

##### Genomics

Boulevard Level B1

**Chairs: Katia Nones, Alan Robertson**

16.30	A molecular tumour board for solid tumours guiding clinical practice and genomics research – Paul Leo
16.49	Genomics is everybody's business: Meeting the needs of the nursing workforce – Cheryl Prescott
17.08	Application of long-read sequencing for cancer genomics – Ann-Marie Patch
17.27	Epigenomic profiling of transposable elements in cancer with Nanopore sequencing – Seth Cheetham
17.46	Integrating sequencing and tissue imaging to find cancer spatial biomarkers – Quan Nguyen

##### Mental Health and Cancer Survivorship

Boulevard Level B2

**Chair: Vanessa Beesley**

16.30	A snapshot of the prevalence of transient, persistent and treatment-resistant anxiety and depression in cancer patients and their carers – Vanessa Beesley
16.50	Systematic review evidence of psychological interventions effective on anxiety and prescribing practices of antidepressants in cancer patients – Saira Sanjida
17.10	What Matters: Developing a measure of wellbeing specifically for Aboriginal and Torres Strait Islander Adults – Kate Anderson
17.30	Barriers to psychosocial care for adolescent and young adult cancer survivors: what do they want, what do they need? – Natalie Bradford
17.50	Discussion/Q&A

##### GU malignancies

Boulevard Level B3

**Chair: Jeff Goh**

16.30	Real world evidence in metastatic renal cell cancer – Chun Loo Gan
16.50	Testis cancer: the iTestis study – Anna Kuchal
17.20	Update on bladder cancer – Niara Oliveira
17.40	Centre for Personalised Analysis of Cancer (C-PAC): bladder cancer organoids – Patrick Thomas

##### Big Data

Boulevard Room

**Chair: David Theile**

16.30	Hitting the jackpot: research in action – Nathan Dunn & Mark Nalder
16.45	Does time to complete breast cancer treatment impact survival? – Euan Walpole
17.00	Are young breast cancer patients receiving guideline concordant care? – Michelle Morris
17.15	Palliative radiation therapy: is there a need to change clinical practice? – Bryan Burmeister
17.30	Blazing new trails in cancer care: introducing the CAQ Innovation Hub – Shoni Philpot
17.45	Panel Discussion/Q&A (Chair – Jason Pole)

7.15pm  
'til late

**Gala Dinner, Boulevard Room, Brisbane Convention and Exhibition Centre**

Opens 7.00am Registration

### Plenary Lectures (8.00–10.00)

Boulevard Auditorium

**Chairs: Fabienne Mackay, Scott Bell**

8.00	Uveal melanoma – Victoria Atkinson
8.17	Role of Radiotherapy in Immunotherapy – Ben Chua
8.34	Gamma knife first 2,500 patients – Mike Jenkins
8.51	Can we identify risk better before a cancer occurs? – Carolyn Mountford
9.08	Lung Cancer screening – Annette McWilliams (Zoom)
9.25	Glycomics & Glycoproteomics in Cancer – Daniel Kolarich
9.42	Concurrent chemoradiotherapy for anal cancer: Quality of life evaluation to improve person-centred care – Pauline Rose

10.00 Refreshments

### Parallel Workshops (10.30–12.00)

**Pharmacy Research & Innovation Roundup**

Arbour Level A1

**Chair: Dan McKavanagh**

10.30	CAR-T Therapy: Role of the Pharmacist – Vivian Day
10.50	Advanced trainee residency program for cancer pharmacists: PAH experience – Marissa Ryan
11.10	Meeting the new cancer care standards as a diverse pharmacy group – Alicia Simpson
11.30	Retrospective review of AKI and initial CSA levels in obese vs non-obese patients in BMT – Jessica McIlwain
11.50	Discussion

**3-D Cancer models**

Arbour Level A2

**Chairs: Laura Bray, Priyakshi Kalita-de Croft**

10.30	Using 3D approaches to improve chemotherapy response in colorectal cancer – Mark Adams
10.45	Liquid biopsy in head and neck cancer – Xi Zhang
11.00	Optical clearing and confocal microscopy: Looking deeper into spheroids – Gency Gunasingh
11.15	Development of an ex vivo pipeline to assess therapeutic response in breast cancer – Madeline Gough
11.30	Optimisation of 3D models of ovarian cancer for extracellular vesicles studies – Nihar Godbole
11.45	Patient-derived explants as a precision medicine therapeutics testing platform – Abby Templeton

**Gynae-oncology**

Boulevard Level B1

**Chairs: Lewis Perrin, John Hooper**

10.30	The ECHO (exercise during chemotherapy for ovarian cancer) trials: an update – Sandi Hayes
10.40	Molecularly targeted ICG for tumour-specific fluorescence-guided surgery for ovarian cancer – Naven Chetty & Yaowu He
10.50	In vitro and in vivo targeting of FGFR in dMMR PDX models – Pam Pollock
11.00	Enhancing anti-tumour immunity in ovarian cancer – Sherry Wu
11.10	Targeting replication stress in Ovarian cancer alters immune detection of the tumour – Brian Gabrielli
11.20	Sentinel Nodes in Endometrial Cancer – Nisha Jagasia
11.30	OCRF-007 – a new biomarker test for early detection of ovarian cancer – Carlos Salomon
11.40	A phase I PET-CT trial for ovarian cancer: establishment phase – John Hooper
11.50	Modifying the toxicities of gynae cancer treatment – Sandie McCarthy

**Brain tumours**

Boulevard Level B2

**Chairs: Mark Pinkham, Zarnie Lwin, Bryan Day**

10.30	Innovative zebrafish models to study dynamic changes in Medulloblastoma tumour vasculature – Anne Lagendijk
10.42	Prolonging survival in glioblastoma by targeting quiescence – Lachlan Harris
10.54	Novel CAR-T cell immunotherapy for glioblastoma – Paulo Martins
11.06	Circulating biomarkers in glioblastoma patients – Juliana Bark
11.18	Telehealth to support patients with brain tumours – Tamara Ownsworth
11.30	Using Artificial Intelligence to improve treatments for brain tumours – Prabhakar Ramachandran
11.42	BRAIn Cancer and Exercise study: exercise safety, feasibility and effect in brain cancer – Gabi Gildea
11.54	Discussion/Q&A



#### Parallel Workshops (10.30–12.00)

##### Thoracic Malignancies

Boulevard Level B3

**Chairs:** Tim Edwards, Connor O'Leary, Morgan Windsor

10.30	Section 1: Early diagnosis/screening – Liquid biopsies: methylscape – Abu Sina – Phospho-proteins – Alain Wuethrich – Breath testing: where are we? – David Fielding
11.00	Section 2: Multi-plex imaging and Digital spatial profiling of NSCLC – Arutha Kulasinghe
11.20	Section 3: Aspiration study – Kenneth O'Byrne
11.30	Section 4: Overcoming therapeutic resistance: potential for modelling – Mark Adams
11.45	Discussion: Bringing Lung Cancer Research Together in Brisbane

##### Immuno-oncology

Boulevard Room

**Chair:** Michelle Wykes

10.30	TIGIT and the conundrum of Hodgkin's Lymphoma – Maher Gandhi
10.45	The emergence of NK cells as a major target in cancer immunotherapy – Fernando Guimaraes
11.00	The application of genomics to explore immune system responses – Anne Marie Patch
11.15	A novel binding partner for PD-L2 – Rebecca Faleiro
11.30	CAR-T cells in clinical practice – Andrea Hendon
11.45	Discussion/Q&A

##### Hepato-biliary cancer

Plaza level P7 & 8

**Chairs:** Vladimir Andelkovic, Thomas O'Rourke

10.30	New targeted treatments in pancreas and cholangiocarcinoma – Harry Gasper
10.40	Pancreatic ductal adenocarcinoma: a collaborative approach to find a potential therapeutic strategy – Emma Karlsen
10.50	Fibroblast Activating Protein Inhibitor: A novel PET tracer to image the tumour microenvironment of pancreatic cancer – Will McGahan
11.00	Immunotherapy in hepatocellular carcinoma: predictive markers and overcoming resistance – Susan Caird
11.10	New generation epi-therapeutics and companion biomarkers towards tackling immunotherapy resistance – Sudha Rao
11.20	The roles of tumour self-seeded cells in liver cancer progression – Haotian Yang
11.30	Treatment-induced ROS contribute to hepatic stellate cell activation in liver cancer – Qi Ruan
11.40	Cholangiocarcinoma: What's next? – Lash Wickramasuriya

**12.00** Lunch

#### Plenary Lectures (12.30–14.00)

Boulevard Auditorium

**Chairs:** Paul Clarke, David Waugh

12.30	Precision medicine for childhood cancer: progress and challenges – Andy Moore
12.48	Difficult decisions in cancer care: risk assessment – Sarah Olsen
13.06	Renal cell cancer: a paradigm for integrating I-O with targeted therapies – Jeff Goh
13.24	Genomics for cancer care: the advocates perspective – Hazel Harden
13.42	Queensland cancer research funding: can we do better? – Frank Gannon & Celia Webby

**14.00** Refreshments



### Parallel Workshops (14.30–16.00)

#### Haematology

Arbour Level A1

##### Chair: Colm Keane

14.30	Factors that regulate response to chemotherapy in myelodysplastic syndromes and acute myeloid leukaemia – Victoria Ling
14.55	Impact of genetics upon the tumour microenvironment in Follicular Lymphoma – Hennes Tsang
15.20	Genomics and Imprecision Medicine – Gregory Corboy
15.45	Discussion/Q&A

#### Palliative Care

Arbour Level A2

##### Chairs: Ben Gunawan, Janet Hardy

14.30	Lymphoedema in patients with head/neck cancer – Taylan Gurgenci
14.45	On patient wellbeing: medicinal Cannabis & 'Wellness' in advanced cancer contexts – Maddison Cuerton & Rebecca Olson
15.00	Are genetic factors associated with fentanyl dose requirements and pain severity in advanced cancer? – John Prenzler & Alison Haywood
15.15	MedCan for kids – Anthony Herbert & Alison Bowers
15.30	Palliative care in the private sector: new models of care – Phillip Good
15.45	Activity monitors the answer for monitoring pain – Sarah Lord

#### Head and neck cancer

Boulevard Level B1

##### Chairs: Sarju Vasani, Rahul Ladwa, Chris Perry

14.30	Failure of Immunotherapy in Head and Neck Cancers – Rahul Ladwa
14.39	Proteomics of HPV-positive oropharyngeal cancer: Targeting non-responders – Christopher Jackson
14.48	Adding a new sting to our bow: spatial profiling of Oropharyngeal Head and Neck cancers – Jazmina Gonzalez Cruz
14.57	Development and validation of the SOSE-H&N distress tool for carers/significant others of patients with head and neck cancer with dysphagia – Rebecca Nund
15.06	Examining the utility of re-staging 18FDG-PET in oropharyngeal cancer: a single site experience – Zhen Liu
15.15	Utilisation of a statewide dataset to examine the impact of remoteness on people with head and neck cancer – Jasmine Foley
15.24	Exploring the role of Immunotherapy in Perineural Spread – Priscila Oliveira De Lima
15.33	Intratumoural immunotherapy in cutaneous SCC – Quentin Wright
15.42	Treatment of perineural spread in cutaneous SCC with immunotherapy – James Nightingale
15.51	Development of Head and Neck cancer Tumouroids – Sarju Vasani

#### GI malignancies

Boulevard Level A2

##### Chairs: Vicki Whitehall, Mark Bettington

14.30	Introduction
14.35	Recent advances in targeted therapies, immunotherapy and clinical trials for colorectal cancer – Marco Matos
14.48	The Rising Incidence of Colorectal Cancer in Young People – Brad Morris
15.01	Pre-treatment DPYD Genotyping – Mark Nalder
15.14	Envoi Pathology: Traditional Serrated Adenomas of the Colorectum – Mark Bettington
15.27	Aspirin and Regorafenib Synergize to Reduce Colorectal Cancer Growth – Chang Su
15.40	KRAS Mutant Colorectal Cancers Segregate into Molecularly and Clinically Distinct Subtypes – Jennifer Borowsky
15.53	Discussion/Q&A

### Parallel Workshops (14.30–16.00)

#### Multimomics

Boulevard Level B3

**Chairs: Arutha Kulasinghe, Sunil Lakhani**

14.30	Computational biology approaches – Melissa Davis (Zoom)
14.40	Spatial single cell atlas in SCC – Laura Grice
14.50	Hairy cell leukemia – Dr Chin Wee Tan (Zoom)
15.00	Skin cancer – Kiarash Khosrotehrani & Chenhao Zhou
15.10	Breast cancer – Alex Swarbrick & Tony Wang (Zoom)
15.20	Melanoma brain metastases – Mitch Stark
15.30	Medulloblastoma – Laura Genovesi
15.40	Compartment-specific gene signatures of immunotherapy response in lung cancer – Arutha Kulasinghe
15.50	Discussion/Q&A

#### Melanoma and skin cancer

Boulevard Room

**Chairs: Jacinta Simmons, Aaron Smith, Nikolas Haass**

14.30	Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma – Gabrielle Belz
14.40	Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression – Brian Gabrielli
14.50	Investigating the mechanism of action and immunotherapeutic potential of tigilanol tiglate in skin cancer – Jason Cullen
15.00	Melanoma cells and their lipid composition while developing drug resistance – Aurélie Benfield
15.10	Microtubule-Dependent Mechanisms of Melanoma Invasion – Robert Ju
15.20	Phenotypic melanoma heterogeneity is regulated through cell-matrix interaction-dependent changes in tumor microarchitecture – Loredana Spoerri
15.30	The protective effect of MC1R r/r on melanoma risk in MITF E318K carriers in high-risk cohorts – Courtney Wallingford
15.40	Genetic and clinical profiling of organ transplant recipients improves prediction of skin cancer risk – Mathias Seviiri
15.50	Development and implementation of a melanoma polygenic risk score in clinical practice – Tatiane Yanes

#### Breast cancer

Plaza level P7 & P8

**Chairs: Juliette French, Pascal Duijf, Fiona Simpson**

14.30	Applications of Spatial Transcriptomics for Cellular Pathology in Breast Cancer – Quan Nguyen
14.48	Linking single-cell noncoding transcriptome to breast cancer – Maina Bitar
15.06	Application of machine learning in breast cancer prognosis by profiling the tumour microenvironment – Olga Kondrashova
15.24	Deciphering the links between chemoresistance and metastasis in breast cancer – Adrian Weigmans & Kate Ivanova
15.42	Calcium signalling in breast cancer brain metastases – Silke Chalmers

**16.00 Refreshments**

### Plenary session (16.15–17.15)


Boulevard Auditorium

**Chairs: Frank Gannon, Matt Trau**


16.15	MRFF breast cancer – Amy McCart Reed
16.23	MRFF Lung Cancer – Pete Simpson
16.31	MRFF MoSTly study – Steve Lane
16.39	CCQ LUCKstars – Bill Dougall
16.47	MoST/ProSPECT – Kenneth O'Byrne
16.55	Discussion

**17.15 – 18.15 Wine and cheese**


# Venue Floor Plans




## Plaza Level



## Boulevard Level



## Arbour Level



# Sponsor Floor Plan

Astrazeneca	1
MSD	2
BMS	3
Bayer	4
Jansen	5
Lilly	6
Pfizer	7
Roche	8
Novartis	9
Amgen	10
Merck	11
Astellia	12
Nanostring	13
Ipsen	14
ThermoFisher	15
Eisai	16
Millenium & 10Xgenomics	17
Takeda	18
BGI	19
Pierre Fabre	20

Qiagen	T1
Servier	T2
TRI	T3
Mundipharma	T4
Aus Genome Research Facility	T5

